Clinical Trial Update: Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing QGE031 (ligelizumab) with placebo and omalizumab to assess efficacy and safety in adults with asthma; results from the completed study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Omalizumab (Omalizumab)
• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-08